Preview Mode Links will not work in preview mode

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

May 24, 2022

What is clinical problem with regard to leaflet thrombosis after TAVR, and what are the main findings of the ADAPT-TAVR trial?

In this interview, Duk-Woo Park, MD and Sun Moon Kim MD, with Zaid I. Almarzooq MBBCh, discuss Late Breaker: Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And...


May 17, 2022

In this interview, Steven E. Nissen, MD, MACC and Anthony N. DeMaria MD, MACC, with Anum Saeed MD, discuss the ACC.22 Late Breaker: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial.


May 10, 2022

Suzanne Oparil, MD, FACC, FAHA, FASH, FAPS and Nanette Kass Wenger MD, MACC, discuss ACC.22 Late Breaker: Antihypertensive Therapy For Mild Chronic Hypertension Improves Pregnancy Outcomes: A Pragmatic Multicenter RCT.


May 3, 2022

In this interview, Steven E. Nissen, MD, MACC and Anthony N. DeMaria MD, MACC, with Anum Saeed MD, discuss the ACC.22 Late Breaker: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial.


Apr 26, 2022

This study evaluates the potential impact of Mavacamten in severely symptomatic patients with obstructive hypertrophic cardiomyopathy to reduce the need for septal reduction therapy. It studies a first of its kind new cardiac myosin inhibitor.

In this interview, Milind Desai MD, MBA and Matthew Martinez MD, FACC, with...